RT Journal Article
SR Electronic
T1 Treatment of chronic hepatitis C with recombinant interferon alfa-2b.
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP S128
OP S129
DO 10.1136/gut.34.2_Suppl.S128
VO 34
IS 2 Suppl
A1 M Piazza
A1 R Orlando
A1 G Tosone
A1 D Tiseo
A1 M C Conte
A1 F Minervini
A1 G Santoro
A1 F Scordino
A1 D Vitale
YR 1993
UL http://gut.bmj.com/content/34/2_Suppl/S128.abstract
AB In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine amino-transferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients.